journal
MENU ▼
Read by QxMD icon Read
search

Heart Failure Clinics

journal
https://www.readbyqxmd.com/read/29153205/biomarkers-of-heart-failure-past-present-and-future
#1
EDITORIAL
Toru Suzuki, Eduardo Bossone
No abstract text is available yet for this article.
January 2018: Heart Failure Clinics
https://www.readbyqxmd.com/read/29153204/proteomic-biomarkers-of-heart-failure
#2
REVIEW
Muhammad Zubair Israr, Liam M Heaney, Toru Suzuki
Heart failure (HF) is associated with significant morbidity and mortality. Biomarkers are used to assist clinicians with timely diagnosis, prognosis, and risk prediction of patients for personalized treatment. Using modern proteomic methods such as mass spectrometry, an increasing number of novel biomarkers have been identified that further aid clinicians in the early diagnosis and outcome prediction of HF. This article focuses on the array of common and novel protein-based biomarkers that provide diagnostic and prognostic information in HF...
January 2018: Heart Failure Clinics
https://www.readbyqxmd.com/read/29153203/galectin-3-in-heart-failure-an-update-of-the-last-3%C3%A2-years
#3
REVIEW
Carolin Gehlken, Navin Suthahar, Wouter C Meijers, Rudolf A de Boer
Galectin-3 plays a role in tissue inflammation, repair, and fibrosis. This article specifically focuses on heart failure (HF), in which galectin-3 has been shown to be a useful biomarker in prognosis and risk stratification, especially in HF with preserved ejection fraction. Experimental research has shown that galectin-3 directly induces pathologic remodeling of the heart, and is therefore considered a culprit protein in the development of cardiac fibrosis in HF, with potentially relevant clinical implications...
January 2018: Heart Failure Clinics
https://www.readbyqxmd.com/read/29153202/growth-hormone-as-biomarker-in-heart-failure
#4
REVIEW
Alberto M Marra, Emanuele Bobbio, Roberta D'Assante, Andrea Salzano, Michele Arcopinto, Eduardo Bossone, Antonio Cittadini
The impairment of growth hormone (GH)/insulin growth factor-1(IGF-1) plays a crucial role in chronic heart failure (CHF). Several studies have shown that patients affected by this condition display a more aggressive disease, with impaired functional capacity and poor outcomes. Interestingly, GH replacement therapy represents a possible future therapeutic option in CHF. In this review, the authors focus on the assessment of the main abnormalities in GH/IGF-1 axis in CHF, the underlying molecular background, and their impact on disease progression and outcomes...
January 2018: Heart Failure Clinics
https://www.readbyqxmd.com/read/29153201/troponin-in-heart-failure
#5
REVIEW
Kevin S Shah, Alan S Maisel, Gregg C Fonarow
Cardiac troponin is an integral biomarker in the evaluation and management of patients with acute coronary syndrome. Troponin is also established as a valuable prognostic marker in patients with acute or chronic heart failure (HF). As the sensitivity of troponin assays transition to high sensitive troponin, more patients with HF will have detectable troponin. In this review, the authors discuss the current literature on the value of troponin in the management of patients with HF. Furthermore, the authors highlight the potential for future strategies to use troponin as a potential target for therapy in patients with HF...
January 2018: Heart Failure Clinics
https://www.readbyqxmd.com/read/29153200/adrenomedullin-as-a-biomarker-of-heart-failure
#6
REVIEW
Toshio Nishikimi, Yasuaki Nakagawa
Adrenomedullin (AM) is a vasodilatory peptide originally discovered in human pheochromocytoma tissue. Although AM is highly expressed in the adrenal glands, heart, lungs, and kidneys, vascular endothelium and smooth muscle are thought to be the main source of plasma AM. The AM precursor is processed to AM-glycine, which is then converted to AM-mature through C-terminal amidation. In this process, mid-regional pro-adrenomedullin (MR-proAM) is also produced. Plasma AM, AM-mature, AM-glycine, and MR-proAM levels are all higher in patients with heart failure than healthy subjects in proportional to the disease severity...
January 2018: Heart Failure Clinics
https://www.readbyqxmd.com/read/29153199/soluble-st2-in-heart-failure
#7
REVIEW
Cian P McCarthy, James L Januzzi
Suppression of tumorigenicity 2 (ST2) is a member of the interleukin (IL)-1 receptor family, whose role was originally established in the context of inflammatory and autoimmune diseases. More recently, testing for ST2 has been used in the setting of cardiovascular disease. The soluble form of ST2 is a decoy receptor that inhibits beneficial cardioprotective effects of IL-33; such inhibition results in cardiac hypertrophy, myocardial fibrosis, and ventricular dysfunction. Measurement of soluble ST2 has utility for assessing heart failure severity and prognosis...
January 2018: Heart Failure Clinics
https://www.readbyqxmd.com/read/29153198/n-terminal-b-type-natriuretic-peptide-in-heart-failure
#8
REVIEW
Arthur Mark Richards
Plasma amino-terminal pro-B-type natriuretic peptide (NT-proBNP) is a guideline-mandated biomarker in heart failure (HF). Used as an inclusion criterion for therapeutic trials, NT-proBNP enriches trial populations and is a valid surrogate endpoint. Its diagnostic performance is best validated in acute decompensated HF (ADHF). NT-proBNP offers prognostic information independent of standard clinical predictors and refines risk stratification. With the advent of combined angiotensin 2 type 1 receptor blockade and neprilysin inhibition (ARNI) NT-proBNP retains its relationship to cardiac status and is the marker of choice in assessment of possible ADHF and in serial monitoring of HF patients receiving ARNI treatment...
January 2018: Heart Failure Clinics
https://www.readbyqxmd.com/read/29153197/natriuretic-peptides-in-heart-failure-atrial-and-b-type-natriuretic-peptides
#9
REVIEW
Alan S Maisel, Jason M Duran, Nicholas Wettersten
The natriuretic peptides play a vital role in normal physiology and as counter-regulatory hormones in heart failure (HF). Clinical assessment of their levels (for B-type natriuretic peptide [BNP], N-terminal proBNP, and the midregion of N-terminal pro-atrial natriuretic peptide) have become valuable tools in diagnosing patients with HF as well as risk stratifying and guiding therapy. Their roles have further expanded beyond HF to other cardiovascular conditions and for risk stratification in asymptomatic individuals...
January 2018: Heart Failure Clinics
https://www.readbyqxmd.com/read/29153196/metabolic-biomarkers-in-heart-failure
#10
REVIEW
Chonyang L Albert, W H Wilson Tang
Metabolomics is the study of small, organic molecules within biochemical pathways. With advancement of technology, nuclear magnetic resonance, gas chromatography, and mass spectrometry have allowed for the discovery and analysis of large databases of metabolites implicated in heart failure. Metabolomics also explores the patient and environment interactions and unlocks the link between environmental exposures and the development of cardiovascular disease. Although a relatively new field, metabolomics is poised to become a clinically impactful field that develops novel biomarkers and explores new therapeutic interventions in heart failure...
January 2018: Heart Failure Clinics
https://www.readbyqxmd.com/read/29153195/proenkephalin-in-heart-failure
#11
REVIEW
Daniel Chu Siong Chan, Thong Huy Cao, Leong Loke Ng
The opioid system is activated in heart failure, which may be cardioprotective but may also be counter-regulatory. Recently, systemic proenkephalin activation has been investigated in various conditions predicting mortality and kidney injury. In acute heart failure, proenkephalin independently predicts mortality and heart failure rehospitalization in addition to traditional risk markers. It also predicts worsening renal function, increasingly recognized as an important risk predictor for poor outcome in heart failure...
January 2018: Heart Failure Clinics
https://www.readbyqxmd.com/read/28865786/a-journey-into-the-science-of-cardiovascular-chronobiology
#12
EDITORIAL
Roberto Manfredini, Eduardo Bossone
No abstract text is available yet for this article.
October 2017: Heart Failure Clinics
https://www.readbyqxmd.com/read/28865785/erratum
#13
(no author information available yet)
No abstract text is available yet for this article.
October 2017: Heart Failure Clinics
https://www.readbyqxmd.com/read/28865784/bedtime-chronotherapy-with-conventional-hypertension-medications-to-target-increased-asleep-blood-pressure-results-in-markedly-better-chronoprevention-of-cardiovascular-and-other-risks-than-customary-on-awakening-therapy
#14
REVIEW
Michael H Smolensky, Ramón C Hermida, Diana E Ayala, Artemio Mojón, José R Fernández
The bases for bedtime hypertension chronotherapy (BHCT) as superior chronoprevention against cardiovascular disease (CVD) are: (1) correlation between blood pressure (BP) and various risks is greater for ambulatory BP monitoring (ABPM) than office BP measurements (OBPM); (2) asleep BP mean is a better predictor of CVD risk than ABPM awake and 24-hour means and OBPM; and (3) targeting of asleep BP by BHCT with one or more conventional medications versus usual on-awakening therapy better reduces major and total CVD events...
October 2017: Heart Failure Clinics
https://www.readbyqxmd.com/read/28865783/bedtime-blood-pressure-chronotherapy-significantly-improves-hypertension-management
#15
REVIEW
Ramón C Hermida, Diana E Ayala, José R Fernández, Artemio Mojón, Juan J Crespo, María T Ríos, Michael H Smolensky
Consistent evidence of numerous studies substantiates the asleep blood pressure (BP) mean derived from ambulatory BP monitoring (ABPM) is both an independent and a stronger predictor of cardiovascular disease (CVD) risk than are daytime clinic BP measurements or the ABPM-determined awake or 24-hour BP means. Hence, cost-effective adequate control of sleep-time BP is of marked clinical relevance. Ingestion time, according to circadian rhythms, of hypertension medications of 6 different classes and their combinations significantly improves BP control, particularly sleep-time BP, and reduces adverse effects...
October 2017: Heart Failure Clinics
https://www.readbyqxmd.com/read/28865782/signal-transduction-and-chronopharmacology-of-regulation-of-circadian-cardiovascular-rhythms-in-animal-models-of-human-hypertension
#16
REVIEW
Björn Lemmer
Inbred strains of rats can be used as models of human hypertension to evaluate mechanisms of regulation of the circadian rhythms underlying hypertension. Blood pressure and heart rate rhythms in rodents are endogenous (circadian). Studies have been performed in rats on the turnover of norepinephrine, on processes of signal transduction in the beta-adrenoceptor-adenylate cyclase-cyclic AMP-phosphodiesterase system and in the renin-angiotensin-aldosterone system, and on circadian rhythms in blood pressure and heart rate using radiotelemetry...
October 2017: Heart Failure Clinics
https://www.readbyqxmd.com/read/28865781/sex-and-circadian-periodicity-of-cardiovascular-diseases-are-women-sufficiently-represented-in-chronobiological-studies
#17
REVIEW
Roberto Manfredini, Raffaella Salmi, Rosaria Cappadona, Fulvia Signani, Stefania Basili, Niki Katsiki
Women are often excluded/underrepresented in clinical trials; sometimes, the number of men/women participants or separate analysis by sex are not reported. A robust body of evidence demonstrated that several life-threatening acute cardiovascular diseases, for example, acute myocardial infarction, sudden cardiac death, cardiac arrest, rupture or dissection of aortic aneurysms, and stroke, exhibit a circadian periodicity with a morning peak. An analysis of 20 years of chronobiologic studies (44% of them, accounting for 85% of total cases, with separate analysis by sex) confirmed that morning hours are a critical time of onset of acute cardiovascular diseases in men and women...
October 2017: Heart Failure Clinics
https://www.readbyqxmd.com/read/28865780/circaseptan-periodicity-of-cardiovascular-diseases
#18
REVIEW
Massimo Gallerani, Marco Pala, Ugo Fedeli
The occurrence of cardiovascular events shows a different distribution during the week, with many studies reporting a Monday peak, possibly related to the role of stress associated with commencing weekly activities. Furthermore, a higher mortality has been observed among patients hospitalized for cardiovascular and other disorders on weekends, a phenomenon known as "weekend effect." Such effect may be explained by a higher level of disease severity among patients admitted over the weekend, and/or by a poorer quality of care associated with shortage of staff, lower experience of personnel, and limited availability of therapeutic and diagnostic procedures...
October 2017: Heart Failure Clinics
https://www.readbyqxmd.com/read/28865779/chronobiology-of-acute-aortic-syndromes
#19
REVIEW
Hasan K Siddiqi, Eduardo Bossone, Reed E Pyeritz, Kim A Eagle
Acute aortic syndromes are highly morbid conditions that require prompt diagnosis and management. Aortic dissections have rhythmic patterns, with notable peaks at certain points in every 24 hours as well as weekly and seasonal variations. Several retrospective studies have assessed the chronobiology of acute aortic dissections and there seems to be a winter seasonal peak and morning daily peak in incidence. Although the pathophysiology of this chronobiology is unclear, there are several environmental and physiologic possibilities...
October 2017: Heart Failure Clinics
https://www.readbyqxmd.com/read/28865778/chronobiologic-aspects-of-venous-thromboembolism
#20
REVIEW
Chiara Fantoni, Francesco Dentali, Walter Ageno
In recent years, several studies have consistently described the chronobiologic aspects of many cardiovascular diseases. Several studies have also assessed the circadian and circannual patterns of occurrence and mortality of deep vein thrombosis and pulmonary embolism, but the results have been less univocal. Different mechanisms have been proposed to explain these possible patterns, including oscillation of coagulation proteins, the role of meteorologic parameters, and air pollution. This article summarizes the available evidence on chronobiologic aspects of venous thromboembolism and discusses the casual mechanism...
October 2017: Heart Failure Clinics
journal
journal
40835
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"